ArticleBioinformation2025
Molecular docking analysis of aldose reductase with herbal compounds from selected siddha medicine for anti-cataract treatment.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inhibitory effects of water chestnut (Journal of diabetes and metabolic disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cataracts are a major cause of blindness and it is due to protein aggregation in the eye lens that is accelerated by aldose reductase (AR)-induced sorbitol accumulation. Therefore, it is of interest to evaluate the anti-cataract potential of six phytochemicals from Siddha medicinal herbs (carinol, voacangine, berberine, piperine, sesamin and isoamericanin A) using molecular docking analysis with human aldose reductase (PDB ID: 4GCA) where epalrestat is used as the standard compound. Analysis shows that berberine, piperine, sesamin and carinol have optimal binding interactions with aldose reductase, performing similar to the standard drug epalrestat having estimated free energy values of -10.37 kcal/mol and -10.13 kcal/mol, respectively for further consideration. Thus, the traditional use of these herbs in Siddha medicine as a potential, affordable and non-surgical cataract-preventative agent is shown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.